Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDe-1 oral PHA-022121 dose-ranging study for acute hereditary angioedema attacks
MOH_2021-02-14_009755Phase 2Completed
- Sponsor
- Pharvaris
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary angioedema (HAE) comparing Part 1 single-dose PHA-022121 with Part 2 crossover PHA-022121/placebo (2 arms). Primary endpoint: Relief of angioedema symptoms during acute attacks. Started Jan 2021; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2021-02-14_009755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-14_009755.